

## Overview

### Useful For

Therapeutic drug monitoring of adalimumab

Quantifying adalimumab antibodies as part of a profile evaluating patients for loss of response, partial response on initiation of therapy, autoimmune or hypersensitivity reactions, primary nonresponse, reintroduction after drug holiday, endoscopic/computed tomography enterography recurrence (in inflammatory bowel disease), acute infusion reactions and proactive monitoring

This test **does not** differentiate between the originator and biosimilar products.

### Testing Algorithm

When this test is ordered, adalimumab quantitation and testing for antibodies-to-adalimumab will always be performed.

### Method Name

Only orderable as part of a profile. For more information see ADALP / Adalimumab Quantitative Antibody, Serum.

Enzyme-Linked Immunosorbent Assay (ELISA)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Specimen Required

Only orderable as part of a profile. For more information see ADALP / Adalimumab Quantitative Antibody, Serum.

**Patient Preparation:** For 12 hours before specimen collection, patient **should not** take multivitamins or dietary supplements (eg, hair, skin, and nail supplements) containing biotin (vitamin B7).

**Supplies:** Sarstedt Aliquot Tube, 5 mL (T914)

**Collection Container/Tube:**

**Preferred:** Serum gel

**Acceptable:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 0.5 mL Serum

**Collection Instructions:**

1. Draw blood immediately before the next dose of drug administration (trough specimen).

2. Centrifuge and aliquot serum into a plastic vial.

**Specimen Minimum Volume**

Serum: 0.35 mL

**Reject Due To**

Gross hemolysis	OK
Gross lipemia	OK
Heat-treated	Reject
Gross icterus	OK

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	28 days	
	Frozen	28 days	

**Clinical & Interpretive****Clinical Information**

Drug and target:

Adalimumab (ADL) is a monoclonal antibody (IgG1 kappa) which targets tumor necrosis factor (TNF)-alpha. TNF-alpha binds to TNF-alpha receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNF-alpha, ADL can reduce the inflammatory response. Because TNF-alpha is also a part of the immune system that protects the body from infection, treatment with ADL may increase the risk of infections. Biosimilars have the same primary amino acid sequence as the reference or originator product. Therefore, ADL will be used to refer to both the reference product and the biosimilar products interchangeably. This test cannot distinguish between the reference product Humira and the ADL biosimilars products.

Indications:

Adalimumab is a subcutaneously administered. It is US Food and Drug Administration-approved for the treatment of multiple immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease (adults and pediatric patients > or =6 years), ulcerative colitis (adults), hidradenitis suppurativa, juvenile idiopathic arthritis (> or =2 years), and non-infectious uveitis. Standard adult maintenance dosing is typically 40 mg subcutaneously every other week, with disease-specific induction regimens for inflammatory bowel disease and hidradenitis suppurativa. Dose escalation to weekly administration may be used in selected patients with inadequate clinical response.

Pharmacokinetics highlights:

Adalimumab has a half-life of approximately 2 weeks. It is usually given as a fixed dose (not weight-based). Peak serum concentrations are achieved approximately 5 days post-dose. Steady-state concentrations are achieved by 3 to 5 months of repeated dosing. Clearance of ADL can be influenced by similar factors as other anti-TNFs: high inflammatory burden,

---

low albumin, and large body mass can increase clearance, while concurrent immunomodulators can reduce immunogenicity and clearance. There is considerable inter-patient variability.

**Immunogenicity:**

Around 30% of patients have no primary response to anti-TNF therapy, and up to 60% of initial responders experience secondary loss of response over time and require either drug dose-escalation or a switch to an alternative therapy in order to maintain response.(1) Reasons for primary loss of response may include disease processes mediated by proinflammatory molecules other than TNF. Secondary loss of response is associated with low serum albumin, high body-mass index, the degree of systemic inflammation and development of immunogenicity.(2,3) Antidrug antibody formation may increase drug clearance in treated patients or neutralize the drug effect, thereby potentially contributing to the loss of response. Antidrug antibodies (ADA) could also cause adverse events such as serum sickness and hypersensitivity reactions.(4) In clinical studies, the incidence of ADA formation varied with dose, concomitant immunosuppressants, and indication, and the presence of antibodies-to-adalimumab (ATA) was associated with lower serum ADL concentrations and, in some analyses, reduced clinical response. Concomitant methotrexate has been shown to reduce the frequency of ATA formation compared with ADL monotherapy. Measurement of ATA is dependent on assay sensitivity and drug tolerance, and comparisons should be made with caution. The clinical implications of ATA positivity should be interpreted in the context of drug concentrations, clinical response, and immunogenicity assay characteristics.

**Evidence for therapeutic drug monitoring:**

Adalimumab therapeutic drug monitoring (TDM) is supported by evidence for both reactive and proactive strategies. Reactive TDM is performed in the setting of loss of response or infusion reactions.(5) Reactive TDM is well validated to distinguish pharmacokinetic failure (low drug, absent antibodies) from immunogenicity (anti-drug antibodies), enabling rational dose escalation or switching and improving cost-effectiveness. Proactive TDM studies, involving routine measurement during maintenance stages of therapy, suggests benefits in reducing immunogenicity, maintaining remission, and optimizing long-term exposure, particularly early in therapy and in high-risk patients.(6,7)

**Reference Values**

[Only orderable as part of profile. For more information see ADALP / Adalimumab Quantitative with Antibody, Serum.](#)

<14.0 AU/mL

**Interpretation**

Low trough concentrations may be associated with loss of response to adalimumab (ADL) due to possible development of an immune response to ADL. Testing for antibodies-to-adalimumab (ATA) is suggested in patients with trough concentrations less than 8.0 mcg/mL.

Adalimumab trough concentrations greater than or equal to 8.0 mcg/mL in patients with loss of response to therapy may suggest possible benefit of treatment with a different monoclonal antibody therapy.

Adalimumab concentrations greater than or equal to 35 mcg/mL suggest possible testing at a time point other than trough and should be evaluated within the clinical context of the patient.

Interpretation and patient management will be different according to disease state, clinical presentation (symptomatic versus appropriate response to therapy), several other laboratory tests and a combination of the drug concentration and/or presence of anti-drug-antibodies.

In the setting of loss of response to ADL therapy for adults with active inflammatory bowel disease (IBD), a clinical decision tool from the American Gastroenterology Association (5,8) suggests the following scenarios for a blood draw that occurred at trough, immediately before the next injection dose:

- For patients who have undetectable or low concentrations of ADL (<8 mcg/mL) but no detectable ATA, the patient care team may choose to increase the dose of ADL in an attempt to increase the amount of the drug in circulation.
- If the patient has subtherapeutic ADL concentrations (<8 mcg/mL) in the presence of an ATA, the patient care team may switch the patient to another tumor necrosis factor inhibitor.
- For patients with increased trough concentrations of ADL (therapeutic or greater), whether an ATA is present or not, it may be necessary to switch the patient to a therapy with a different mechanism of action such as the anti-alpha4-beta7-integrin antibody vedolizumab or the interleukin (IL)-12/IL-23 antibodies.

Test interpretation relies on clinical presentation and may differ from the statements above, which were designed for adults with IBD experiencing loss of response. For individuals on ADL therapy for other conditions such as rheumatoid arthritis, or pediatric patient populations or proactive monitoring, drug concentration therapeutic targets and patient management decision may be individualized. When both the drug quantitation and anti-drug-antibodies are ordered, an interpretive guide is offered below.

Adalimumab quantitation, mcg/mL	Antibody-to-adalimumab, AU/mL	Comment
<8	Negative	Absence of detectable antibody-to-adalimumab (ATA). Low concentration of ADL may be attributable to other parameters related to ADL clearance.
<8	Positive	Presence of ATA detected, which correlates with low concentration of ADL.  ATA may be associated with increased clearance and lower circulating concentrations of ADL.
8.1-15	Negative	Absence of detectable ATA.  At this concentration of ADL, a low-titer (50-150 AU/mL) or moderate titer (150-500 AU/mL) ATA cannot be excluded. However, the presence of a high-titer ATA (> or =500 U/mL) is unlikely.  If there is clinical suspicion for a low-titer ATA, suggest submission of a new sample obtained at trough.  This test has demonstrated drug tolerance up to 40 mcg/mL for ATA > or = 500 AU/mL, up to 15 mcg/mL for ATA between 150-500 and up to 8 mcg/mL ADL for ATA between 50-150 AU/mL.
	Low or moderate	Presence of ATA detected. At this concentration of ADL, the detected titer of the ATA may be modestly underestimated.

	positive (14-499)	This test has demonstrated drug tolerance up to 40 mcg/mL for ATA > or =500 AU/mL, up to 15 mcg/mL for ATA between 150-500 and up to 8 mcg/mL ADL for ATA between 50-150 AU/mL.
	High positive (> or =500)	Presence of ATA detected.  This test has demonstrated drug tolerance up to 40 mcg/mL for ATA > or =500 AU/mL, up to 15 mcg/mL for ATA between 150-500 and up to 8 mcg/mL ADL for ATA between 50-150 AU/mL.
>15	Negative	At this concentration of ADL, a low (50-150 AU/mL) or moderate titer (150-500 AU/mL) ATA cannot be excluded. The presence of a high-titer ATA (> or =500 U/mL) is unlikely but also cannot be completely excluded.  If there is clinical suspicion for an ATA, suggest submission of a new sample obtained at trough, preferably during the maintenance phase of therapy.  This test has demonstrated drug tolerance up to 40 mcg/mL for ATA > or =500 AU/mL, up to 15 mcg/mL for ATA between 150-500 and up to 8 mcg/mL ADL for ATA between 50-150 AU/mL.
	Low positive (14-149)	Presence of ATA detected. At this concentration of ADL, the detected titer of the ATA is likely underestimated.  Suggest submission of a new sample obtained at trough, preferably during the maintenance phase of therapy.  This test has demonstrated drug tolerance up to 40 mcg/mL for ATA > or =500 AU/mL, up to 15 mcg/mL for ATA between 150-500 and up to 8 mcg/mL ADL for ATA between 50-150 AU/mL.
	Moderate positive (150-499 U/mL)	Presence of ATA detected. At this concentration of ADL, the detected titer of the ATA may be underestimated.  Suggest submission of a new sample obtained at trough, preferably during the maintenance phase of therapy.  This test has demonstrated drug tolerance up to 40 mcg/mL for ATA > or =500 AU/mL, up to 15 mcg/mL for ATA between 150-500 and up to 8 mcg/mL ADL for ATA between 50-150 AU/mL.
	High positive (> or =500)	Presence of ATA detected.  This test has demonstrated drug tolerance up to 40 mcg/mL for ATA > or =500 AU/mL, up to 15 mcg/mL for ATA between 150-500 and up to 8 mcg/mL ADL for ATA between 50-150 AU/mL.

**Cautions**

Tumor necrosis factor (TNF) measurement is not the analyte of choice for monitoring therapy with TNF inhibitors (such as adalimumab [ADL] or infliximab), since TNF testing would not distinguish between free TNF and TNF bound to the monoclonal antibody, either in the extracellular or membrane-bound form of the cytokine.

While the immunogenicity rates between reference product and biosimilars are similar, there could be epitope differences in the anti-drug-antibodies for each formulation.

Toxicity effects other than acute hypersensitivity infusion reactions have not been described nor correlated with high ADL concentrations.

For patients taking biotin supplements, it is recommended to wait at least 12 hours after the last ingestion of biotin to collect a blood sample for this test.

The presence of ADL in patients' serum is a recognized interference in most adalimumab antibodies (ATA) methods. The ATA assay includes an acid dissociation step, which partially mitigates this interference. The best timeframe for a blood draw for therapeutic drug monitoring is at trough, immediately before the next dose of the medication.

This test is designed to quantify adalimumab antibodies regardless of formulation. It is suitable for testing both the reference product and all US Food and Drug Administration and European Medicines Agency approved biosimilars. The assay does not differentiate between the originator and biosimilar products.

**Clinical Reference**

1. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. *Transl Res.* 2015;165(2):270-282
2. Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. *Clin Pharmacol Ther.* 2012;91(4):635-646
3. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2012;10(10):1079-e86
4. Restellini S, Chao CY, Lakatos PL, et al. Therapeutic drug monitoring guides the management of Crohn's patients with secondary loss of response to adalimumab. *Inflamm Bowel Dis.* 2018;24(7):1531-1538
5. American Gastroenterological Association. Therapeutic drug monitoring in inflammatory bowel disease: Clinical decision support tool. *Gastroenterology.* 2017;153(3):858-859. doi:10.1053/j.gastro.2017.07.039
6. Irving PM, Gecse KB. Optimizing therapies using therapeutic drug monitoring: Current strategies and future perspectives. *Gastroenterology* 2022;162(5):1512-1524
7. Yao J, Jiang X, You JHS. Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: a cost-effectiveness analysis. *J Gastroenterol Hepatol.* 2021;36(9):2397-2407. doi:10.1111/jgh.15373
8. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. *Gastroenterology.* 2017;153(3):827-834. doi:10.1053/j.gastro.2017.07.032
9. Kato M, Sugimoto K, Ikeya K, et al. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. *PLoS One.* 2021;16(7):e0254548
10. Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases.

Gastroenterology. 2017;153(3):835-857.e6. doi:10.1053/j.gastro.2017.07.031

11. Sejournet L, Kerever S, Mathis T, Kodjikian L, Jamilloux Y, Seve P. Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study. Br J Ophthalmol. 2022;106(10):1380-1386. doi:10.1136/bjophthalmol-2021-319072

12. Gomez-Arango C, Gorostiza I, Ucar E, et al. Cost-effectiveness of therapeutic drug monitoring-guided adalimumab therapy in rheumatic diseases: A Prospective, Pragmatic Trial. Rheumatol Ther. 2021;8(3):1323-1339. doi:10.1007/s40744-021-00345-5

13. Abdalla T, Mansour M, Bouazzi D, Lowes MA, Jemec GBE, Alavi A. Therapeutic drug monitoring in patients with suboptimal response to adalimumab for hidradenitis suppurativa: A retrospective case series. Am J Clin Dermatol. 2021;22(2):275-283. doi:10.1007/s40257-020-00575-3

## Performance

### Method Description

Testing for antibodies-to-adalimumab is performed using a laboratory-developed immunoassay.(Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Tuesday, Friday

### Report Available

3 to 6 days

### Specimen Retention Time

14 days

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Superior Drive

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

83520

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
ABADL	Adalimumab Ab, S	No LOINC Needed

Result ID	Test Result Name	Result LOINC® Value
ABADL	Adalimumab Ab, S	90779-0